U-R-Immune Glioma (CA209-1245): A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
Latest Information Update: 23 May 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
Most Recent Events
- 15 May 2025 Status changed from not yet recruiting to recruiting.
- 04 Dec 2024 Planned primary completion date changed from 1 Aug 2026 to 1 Dec 2026.
- 04 Dec 2024 Planned initiation date changed from 1 Aug 2024 to 1 Dec 2024.